These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 26779616)

  • 61. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.
    Kairemo K; Milton DR; Etchebehere E; Rohren EM; Macapinlac HA
    Curr Radiopharm; 2018; 11(2):147-152. PubMed ID: 29956640
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity.
    Gómez-Veiga F; Álvarez-Ossorio JL; Carballido-Rodríguez J; Juárez-Soto A; Rodríguez-Antolín A; Cozar-Olmo JM
    Actas Urol Esp (Engl Ed); 2018 Dec; 42(10):616-624. PubMed ID: 30041891
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Kim SI; Szeto AH; Morgan KP; Brower B; Dunn MW; Khandani AH; Godley PA; Rose TL; Basch EM; Milowsky MI; Whang YE; Crona DJ
    PLoS One; 2021; 16(6):e0253021. PubMed ID: 34153052
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
    Shore N; Higano CS; George DJ; Sternberg CN; Saad F; Tombal B; Miller K; Kalinovsky J; Jiao X; Tangirala K; Sartor O
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):680-688. PubMed ID: 32404868
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
    McGann S; Horton ER
    Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
    Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
    Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study.
    Hyväkkä A; Kääriäinen OS; Utriainen T; Löyttyniemi E; Mattila K; Reinikainen P; Sormunen J; Jääskeläinen M; Auvinen P; Minn H; Sundvall M
    Cancer Med; 2023 Feb; 12(4):4064-4076. PubMed ID: 36156455
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical response to radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.
    Zhang I; Gilbo P; Kohn N; Cox B
    Pract Radiat Oncol; 2018; 8(6):452-457. PubMed ID: 29934137
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
    Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
    Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group.
    O'Sullivan JM; Carles J; Cathomas R; Gomez-Iturriaga A; Heinrich D; Kramer G; Ost P; van Oort I; Tombal B
    Eur Urol Oncol; 2020 Aug; 3(4):455-463. PubMed ID: 31411991
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
    Wilson JM; Parker C
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):911-8. PubMed ID: 27501059
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Practical guide to the use of radium 223 dichloride.
    Den RB; Doyle LA; Knudsen KE
    Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
    Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
    Jong JM; Oprea-Lager DE; Hooft L; de Klerk JM; Bloemendal HJ; Verheul HM; Hoekstra OS; van den Eertwegh AJ
    Eur Urol; 2016 Sep; 70(3):416-26. PubMed ID: 26391636
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impact of pre-treatment variables on the completion of
    Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
    Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
    Dorff TB; Gross ME
    Am Soc Clin Oncol Educ Book; 2015; ():e270-3. PubMed ID: 25993185
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Radium-223 treatment of bone metastases from castration-resistant prostate cancer].
    Mortensen J; Højgaard L
    Ugeskr Laeger; 2014 Jul; 176(30):1399-402. PubMed ID: 25292232
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
    Anido Herranz U; Fernández Calvo O; Afonso Afonso FJ; Rodríguez Martínez de Llano S; Lázaro Quintela M; León Mateos L; Vázquez Estévez S; Antón Aparicio LM
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):339-48. PubMed ID: 25555355
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.
    Delacruz A; Arauz G; Curley T; Lindo A; Jensen T
    Clin J Oncol Nurs; 2015 Apr; 19(2):E31-5. PubMed ID: 25840395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.